Contract drug manufacturer Patheon has announced that Robert Tedford has turned in his resignation 10 months ahead of schedule. Patheon chairman Peter Green, president and CEO Nick DiPietro, and CFO and executive vice-president Douglas Ludwig have formed the "office of the chief executive."
Raven biotechnologies has named George F. Schreiner, M.D., Ph.D., as CEO and director.
Drug marketing company PDI has named Michael Marquand as its new CEO, replacing interim CEO Larry Ellberger.
Calypte Biomedical announced that Roger I. Gale, chairman of the board since November 2004, has been appointed president and CEO.
Epix Pharmaceuticals announced that Michael Astrue has resigned as interim CEO.
BioPheresis Technologies has named Bernhard R. M. Ehmer, MD, chief CEO.
ImpactRx announced that CEO and President Nancy Lurker will be leaving the company to take a new job.
Immtech Pharmaceuticals announced the retirement of T. Stephen Thompson, president and member of its board of directors.
AVANIR Pharmaceuticals announced that Michael J. Puntoriero has joined the company as senior vice president of finance and, effective May 15, 2006, will be appointed CFO.
NeoPharm announced the resignation of Imran Ahmad as executive vice president and chief scientific officer.
Pharmacopeia CFO Michio Soga is resigning to pursue other opportunities.
Ambrx announced the appointment of Hazel M. Aker as senior vice president of operations and business affairs.
Biovail Corporation has named Dr. Peter Silverstone senior vice-president, medical and scientific affairs.
David J. Tyler has joined ChondroGene as director, product development and quality assurance.
Pro-Pharmaceuticals has retained James T. Gourzis, M.D., Ph.D., on a consulting basis to provide clinical management and strategic development of its Europe-based Phase III colorectal cancer trial.
Neose Technologies has elected L. Patrick Gage, Ph.D. as non-executive chairman of the board.
Avecia has announced a new three-man board for its parent, Avecia Holdings. They are: CEO & Director Adrian Buckmaster; CFO Duncan McLellan; and Executive Director Dr. Kevin Cox.
INNOVIVE Pharmaceuticals has elected Neil Herskowitz to its board of directors.
Dr. Brian Adger has been appointed as chairman of De Novo Pharmaceuticals' new Scientific Advisory Board, together with Dr. John Dixon and Dr. Peter Warne.
Othera Pharmaceuticals has elected Katherine Crothall, Ph.D. and Bruce A. Peacock to its board of directors.